Comparison of Sacral Erector Spinae Plane Block and Supra-Inguinal Fascia Iliaca Block for Analgesia After Hip Fracture Surgery
NCT ID: NCT07081867
Last Updated: 2026-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
77 participants
OBSERVATIONAL
2025-01-15
2025-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of QIPB and SIFICB in Hip Surgery
NCT07233746
Comparison Effects of Two Regional Anesthetic Technique on Pain During High Risk Hip Fracture Surgery
NCT05862922
PENG vs SIFI Block for Positioning Pain During Spinal Anesthesia
NCT05549011
Iliopsoas Plane Block vs PENG Block for Hip Arthroplasty
NCT05397145
Postoperative Analgesia in Hip Arthroplasty
NCT07153575
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Regional anesthesia techniques, including Sacral Erector Spinae Plane Block (SESPB) and Supra-Inguinal Fascia Iliaca Block (SIFIB), have gained popularity as part of multimodal analgesia strategies that aim to minimize opioid use and improve postoperative comfort. However, there is limited evidence comparing these two techniques directly.
In this prospective observational study, patients aged 65 and older undergoing hip fracture surgery under spinal anesthesia were included. After obtaining informed consent, patients received either SESPB or SIFIB for postoperative analgesia in addition to the standard anesthetic protocol.
Pain levels were assessed using the Visual Analog Scale (VAS) at 1, 6, 12, and 24 hours after surgery. Additional data such as total opioid consumption within 24 hours, time to first analgesic requirement, mobilization time, and length of hospital stay were recorded.
The results demonstrated that patients who received SIFIB had significantly lower pain scores in the early postoperative period (1st hour), while patients who received SESPB experienced better pain relief in the late postoperative period (24th hour). No significant differences were observed between the groups in terms of total opioid consumption, mobilization time, or hospital stay duration. No complications related to the block procedures were reported.
This study suggests that both SESPB and SIFIB are safe and effective regional anesthesia techniques for postoperative pain management in hip fracture surgeries. The selection between these blocks may be based on the desired onset and duration of analgesia, with SIFIB providing superior early pain control and SESPB offering more prolonged analgesic effects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SIFIB Group
Patients who underwent Supra-Inguinal Fascia Iliaca Block (n=40)
Supra-inguinal Fascia Iliaca Block (SIFIB)
Ultrasound-guided injection of 40 mL of 0.25% bupivacaine between the iliacus muscle and fascia iliaca via a supra-inguinal approach, performed preoperatively for postoperative analgesia in patients undergoing hip fracture surgery under spinal anesthesia.
SESPB Group
Patients who underwent Sacral Erector Spinae Plane Block (n=37)
Sacral Erector Spinae Plane Block (SESPB)
Ultrasound-guided injection of 40 mL of 0.25% bupivacaine into the fascial plane deep to the erector spinae muscle at the sacral level (S2), performed preoperatively for postoperative analgesia in patients undergoing hip fracture surgery under spinal anesthesia.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Supra-inguinal Fascia Iliaca Block (SIFIB)
Ultrasound-guided injection of 40 mL of 0.25% bupivacaine between the iliacus muscle and fascia iliaca via a supra-inguinal approach, performed preoperatively for postoperative analgesia in patients undergoing hip fracture surgery under spinal anesthesia.
Sacral Erector Spinae Plane Block (SESPB)
Ultrasound-guided injection of 40 mL of 0.25% bupivacaine into the fascial plane deep to the erector spinae muscle at the sacral level (S2), performed preoperatively for postoperative analgesia in patients undergoing hip fracture surgery under spinal anesthesia.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients undergoing surgery for hip fractures under spinal anesthesia
* Patients who are oriented and cooperative
* Patients who have signed an informed consent form
Exclusion Criteria
* Patients with Alzheimer's disease or dementia, and those who are non-oriented or non-cooperative
* Patients with major organ failure (such as heart, liver, or kidney failure)
* Patients who decline to participate in the study
* Patients classified as American Society of Anesthesiologists (ASA) Physical Status IV or higher
* Patients with pathological fractures or bone metastasis
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Beyzanur Aydoğdu
Resident Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Beyzanur Aydogdu
Role: PRINCIPAL_INVESTIGATOR
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Istanbul, Sisli, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CT-ERHO-AR-BA-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.